X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences
X4 Pharmaceuticals (Nasdaq: XFOR) announced management participation in two significant events: the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 2:00 PM ET, and the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 12:25 PM ET. A live webcast will be available for the latter, hosted on their investor website and archived for about 90 days. X4 is focused on developing therapies targeting diseases caused by CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, currently in Phase 3 trials for WHIM syndrome and Phase 1b trials for other conditions.
- None.
- None.
BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit.
Details are as follows:
Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit
Date: Thursday, May 20, 2021
Time: 2:00 PM ET
Conference: Oppenheimer Rare & Orphan Disease Summit
Date: Friday, May 21, 2021
Time: 12:25 PM ET
Presentation Webcast Link
A live webcast of the Oppenheimer Rare & Orphan Disease Summit presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. Following the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.
Investors and Media:
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com
FAQ
What events will XFOR participate in May 2021?
When is X4 Pharmaceuticals' webcast presentation?
What is the focus of X4 Pharmaceuticals' lead candidate mavorixafor?
Where can I find the webcast of X4 Pharmaceuticals' presentation?
What clinical trials is X4 Pharmaceuticals currently conducting?
